Although molecular-targeted therapy has been confirmed as first-line therapy option for those advanced NSCLC with driver gene mutations, including epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), and KRAS mutations in recent years, still majority of NSCLC patients are not indicated to adopt molecular-targeted therapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.